GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.
Maceski AM
,
Benkert P
,
Einsiedler M
,
Schaedelin S
,
Oechtering J
,
Melie-Garcia L
,
Cagol A
,
Galbusera R
,
Galli E
,
Mueller J
,
Finkener S
,
Lalive PH
,
Uginet M
,
Müller S
,
Pot C
,
Mathias A
,
Du Pasquier R
,
Hoepner R
,
Chan A
,
Disanto G
,
Zecca C
,
D'Souza M
,
Hemkens LG
,
Yaldizli Ö
,
Derfuss T
,
Roth P
,
Gobbi C
,
Brassat D
,
Tackenberg B
,
Pedotti R
,
Raposo C
,
Oksenberg J
,
Green AJ
,
Wiendl H
,
Berger K
,
Hermesdorf M
,
Piehl F
,
Conen D
,
Kappos L
,
Khalil M
,
Granziera C
,
Abdelhak A
,
Leppert D
,
Willemse EAJ
,
Kuhle J
,
Brain : a journal of neurology -
Nov 2025